Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapy in Europe IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS and BOSTON, May 10, 2023 /PRNewswire/ — Servier, a global…